Evidence map›Paper›PMID 24484870›Full record

ArticleLeukemia research2014

miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.

Melanie L Ufkin, Sarah Peterson, Xuehui Yang, Heather Driscoll, Christine Duarte, Pradeep Sathyanarayana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. MircoRNAs predict and modulate responses to chemotherapy in leukemic patients.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. The miR-125a-3p Inhibits TIM-3 Expression in AML Cell Line HL-60 In Vitro.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Melanie L UfkinThe Graduate School of Biomedical Sciences, University of Maine, Orono, ME, USA; Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA.
Sarah PetersonThe Graduate School of Biomedical Sciences, University of Maine, Orono, ME, USA; Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA.
Xuehui YangCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA.
Heather DriscollBioinformatics Support and Outreach, Vermont Genetics Network, Department of Biology and Physical Education, Norwich University, Northfield, VT, USA.
Christine DuarteCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA.
Pradeep SathyanarayanaThe Graduate School of Biomedical Sciences, University of Maine, Orono, ME, USA; Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA. Electronic address: sathyp@mmc.org.
Maine Medical Center Research Institute · USNorwich University Applied Research Institute · USUniversity of Maine · US

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CHRISTOPHER S FRANCKLYN · 2012 to 2026
$58.4M
WNT SIGNALING IN PREIMPLANTATION EMBRYOP20RR018789 · NCRR · MAINE MEDICAL CENTER · PI WOJCHOWSKI, DON MICHAEL · 2003 to 2011
$18.9M
Progenitor Cell Analysis CoreP30GM106391 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2013 to 2017
$5.7M
Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
COBRE in Stem Cell Biology and Regenerative MedicineP20GM103465 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2012 to 2012
$2.0M
NCRR NIH HHS P20 RR018789NIGMS NIH HHS 5P30GM103392NIGMS NIH HHS 8P20GM103449NIGMS NIH HHS 8P20GM103465NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P20 GM103465NIGMS NIH HHS P30 GM103392NIGMS NIH HHS P30 GM106391
6 · The paper itself

Abstract

microRNA profiling of acute myeloid leukemia patient samples identified miR-125a as being decreased. Current literature has investigated miR-125a's role in normal hematopoiesis but not within acute myeloid leukemia. Analysis of the upstream region of miR-125a identified several CpG islands. Both precursor and mature miR-125a increased in response to a de-methylating agent, Decitabine. Profiling revealed the ErbB pathway as significantly decreased with ectopic miR-125a. Either ectopic expression of miR-125a or inhibition of ErbB via Mubritinib resulted in inhibition of cell cycle proliferation and progression with enhanced apoptosis revealing ErbB inhibitors as potential novel therapeutic agents for treating miR-125a-low AML.

Indexed as

Gene Expression Regulation, LeukemicAnimalsAntimetabolites, AntineoplasticApoptosisAzacitidineCell CycleCell ProliferationCpG IslandsDecitabineHematopoiesisHumansLeukemia, Myeloid, AcuteMiceMice, Inbred NODMicroRNAsOncogene Proteins v-erbBAntimetabolites, AntineoplasticAzacitidineDecitabineMicroRNAsMIRN125 microRNA, humanOncogene Proteins v-erbBApoptosisCell cycleMethylationmicroRNA-125aMubritinib

Identifiers

PMID24484870
PMCPMC4117580
OpenAlexW2070249425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.